Elsevier

Clinical Therapeutics

Volume 28, Issue 6, June 2006, Pages 801-831
Clinical Therapeutics

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature

https://doi.org/10.1016/j.clinthera.2006.06.003Get rights and content

Background:

Erythropoiesis-stimulating proteins (ESPs) are indicated for the treatment of chemotherapy-induced anemia (CIA). Evidence-based guidelines and systematic reviews of the management of CIA do not yet include all currently approved ESPs or all of the clinically relevant benefits and risks of ESPs.

Objectives:

The aims of this work were to provide up-to-date assessments of the clinical efficacy and effectiveness (ie, transfusions and quality-of-life [QoL] benefits) and safety (ie, risk of venous thromboembolism [VTE] and all-cause or treatment-associated death) of epoetin-alfa, epoetin-β, and darbepoetin-alfa for the treatment of CIA in cancer patients with hemoglobin <11 g/dL. We also considered the impact of differences in study design, patients, and treatments on the results.

Methods:

A systematic review of the literature was performed to identify and analyze English-language studies (controlled trials and prospective uncontrolled studies with ≥300 patients) published between 1980 and July 2005. The databases searched were MEDLINE and the Cochrane Library. Relevant abstracts from the last 2 annual meetings of the American Society of Clinical Oncology, American Society of Hematology, and European Society for Medical Oncology were also included. Studies were selected, using predefined eligibility criteria. Two reviewers had to agree on all included and excluded studies, and on all data extracted from each accepted study before they were entered into a relational database. Meta-analyses were performed to quantify benefit and risk outcomes.

Results:

In total, 40 studies including 21,378 patients were eligible for analysis. Each ESP was found to have efficacy relative to standard care or placebo. The odds ratio (OR) for transfusions in studies of epoetin versus controls was 0.44 (95% CI, 0.35–0.55) and of darbepoetin versus controls was 0.41 (95% CI, 0.31–0.55). Patients receiving ESPs experienced a significant improvement in QoL; the mean difference in Functional Assessment of Cancer Therapy-Fatigue score for ESPs versus controls was 0.23 (95% CI, 0.10–0.36; P = 0.001). The frequency of VTE and death was not significantly different between ESPs and control (VTE OR, 1.41 [95% CI, 0.81–2.47]; all-cause mortality OR, 1.00 [95% CI, 0.69–1.44]).

Conclusions:

This analysis of key clinical benefits and risks of epoetin and darbepoetin in the treatment of CIA found no clinically relevant differences between these drugs.

References (71)

  • OberhoffC. et al.

    Recombinant human erythropoietin in the treatment of chemotherapy induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study

    Ann Oncol.

    (1998)
  • PorterJ.C. et al.

    Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized, double-blind, placebo-controlled trial

    J Pediatr.

    (1996)
  • SavonijeJ.H. et al.

    Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinumbased chemotherapy: Results of a multicenter randomised controlled trial

    Eur J Cancer

    (2005)
  • GamucciT. et al.

    Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin

    Eur J Cancer

    (1993)
  • HenkeM. et al.

    Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial

    Lancet

    (2003)
  • O'ShaughnessyJ.A. et al.

    Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy

    Clin Breast Cancer

    (2005)
  • CasadevallN. et al.

    Health, economic, and qualityof-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial

    Blood

    (2004)
  • LudwigH. et al.

    Prediction of response to erythropoietin treatment in chronic anemia of cancer

    Blood

    (1994)
  • National Comprehensive Cancer Network

    Clinical practice guidelines in oncology: Cancer and treatment-related anemia

  • BohliusJ. et al.

    Erythropoietin for patients with malignant disease

    Cochrane Database Syst Rev

    (2004)
  • QuirtI. et al.

    Role of erythropoietin in the management of cancer patients with nonhaematologic malignancies receiving chemotherapy

    Curr Oncol

    (2003)
  • US Food and Drug Administration

    Oncologic Drugs Advisory Committee

    (May 4, 2004)
  • CookD.J. et al.

    Systematic reviews: Synthesis of best evidence for clinical decisions

    Ann Intern Med

    (1997)
  • Aranesp [package insert]

    (2005)
  • Procrit [package insert]

    (2005)
  • MantelN. et al.

    Statistical aspects of the analysis of data from retrospective studies of disease

    J Natl Cancer Inst

    (1959)
  • FleissJ.L.

    Statistical Methods for Rates and Proportions

    (1973)
  • PetittiD.B.

    Meta-Analysis, Decision Analysis, Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine

    (1994)
  • HedgesL.V. et al.

    Statistical Methods for Meta-analysis

    (1985)
  • AravantinosG. et al.

    Recombinant human erythropoietin for platinum-based chemotherapyinduced anaemia: A single-centre randomised study

    J Balkan Union Oncol

    (2003)
  • BoogaertsM. et al.

    Impact of epoetin beta on quality of life in patients with malignant disease

    Br J Cancer

    (2003)
  • CascinuS. et al.

    Recombinant human erythropoietin treatment in platinum-associated anemia: A randomized, double-blind trial with placebo

    J Clin Oncol

    (1994)
  • DammaccoF. et al.

    The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy

    Int J Clin Lab Res

    (1998)
  • LittlewoodT.J. et al.

    Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial

    J Clin Oncol

    (2001)
  • Cited by (108)

    • A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia

      2018, Critical Reviews in Oncology/Hematology
      Citation Excerpt :

      No significant difference in HRQoL improvement between epoetin and darbepoetin was reported in the identified SLRs (Minton et al., 2008; Ross et al., 2006; Tonelli et al., 2009; Wilson et al., 2007). Ross et al. (2006) reviewed 40 studies and indicated that no clear superiority of one agent over the other could be established for transfusions and HRQoL outcomes in patients with CIA. Thirteen SLRs evaluated the safety of ESAs in patients with CKD-IA (Alsalimy and Awaisu, 2014; Vinhas et al., 2012; Phrommintikul et al., 2007; Strippoli et al., 2004; Hahn et al., 2017; Cody and Hodson, 2016; Covic et al., 2014; Koulouridis et al., 2013; Marin et al., 2014; Palmer et al., 2010; Saglimbene et al., 2017; Wilhelm-Leen and Winkelmayer, 2015; Tonelli et al., 2008b).

    • Erythropoietin and Nonhematopoietic Effects

      2017, American Journal of the Medical Sciences
      Citation Excerpt :

      EPO is used for the treatment of anemia associated with chronic renal failure and chemotherapy.2,3 Several well-established studies have shown that in adults, the kidney is the main source of the circulating EPO, where this hormone is responsible for maintaining the red blood cell mass.4,5 EPO prevents programmed cell death (apoptosis) of erythrocyte precursors.6,7

    • Update on erythropoiesis-stimulating agents

      2013, Best Practice and Research: Clinical Anaesthesiology
      Citation Excerpt :

      The risks of death or cardiovascular events were also associated with a poor initial haematopoietic response, as doses of ESAs were escalated to meet target Hgb levels.18 Literature reviews and meta-analyses of clinical trials of ESA therapy both in approved settings and in off-label clinical trial designs have analysed survival and other safety outcomes.11,22,29–35 Overall, three meta-analyses31,32,34 indicated increased risk of mortality with the use of ESA, whereas two33,35 indicated that ESA did not significantly affect mortality.

    View all citing articles on Scopus
    View full text